Literature DB >> 16942821

Risk assessment for glucosamine and chondroitin sulfate.

John N Hathcock1, Andrew Shao.   

Abstract

Glucosamine and chondroitin sulfate are two popular dietary ingredients present in dietary supplements intended to support joint health. A large body of human and animal research suggests that oral intakes of these ingredients, either alone or in combination, reduces joint pain and improves mobility in persons with osteoarthritis. The increased awareness and use of these ingredients in dietary supplements warrant a comprehensive review of their safety. Systematic evaluation of the research designs and data do not provide a basis for risk assessment and the usual safe upper level of intake (UL) derived from it unless the newer methods described as the observed safe level (OSL) or highest observed intake (HOI) are utilized. The OSL risk assessment method indicates that the evidence strongly supports safety at intakes up to 2000 mg/d for glucosamine, and 1200 mg/d for chondroitin sulfate, and these levels are identified as the respective OSL. These values represent the highest levels tested in human clinical trials. The complete absence of adverse effects at these levels supports a confident conclusion of their long-term safety.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16942821     DOI: 10.1016/j.yrtph.2006.07.004

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  16 in total

1.  Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled pilot study using MRI.

Authors:  J-J Railhac; M Zaim; A-S Saurel; J Vial; B Fournie
Journal:  Clin Rheumatol       Date:  2012-06-23       Impact factor: 2.980

2.  Effects of chondroitin sulfate and glucosamine in adult patients with Kaschin-Beck disease.

Authors:  Ya-xu Zhang; Wei Dong; Hui Liu; Flavia Cicuttini; Maximilian de Courten; Jian-bai Yang
Journal:  Clin Rheumatol       Date:  2010-01-28       Impact factor: 2.980

3.  Multiorgan dysfunction syndrome secondary to joint supplement overdosage in a dog.

Authors:  Irma J Nobles; Safdar Khan
Journal:  Can Vet J       Date:  2015-04       Impact factor: 1.008

Review 4.  Type 2 diabetes mellitus and osteoarthritis.

Authors:  Nicola Veronese; Cyrus Cooper; Jean-Yves Reginster; Marc Hochberg; Jaime Branco; Olivier Bruyère; Roland Chapurlat; Nasser Al-Daghri; Elaine Dennison; Gabriel Herrero-Beaumont; Jean-François Kaux; Emmanuel Maheu; René Rizzoli; Roland Roth; Lucio C Rovati; Daniel Uebelhart; Mila Vlaskovska; André Scheen
Journal:  Semin Arthritis Rheum       Date:  2019-01-11       Impact factor: 5.532

5.  The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.

Authors:  Ruiting Lin; Siyuan Xia; Changliang Shan; Dong Chen; Yijie Liu; Xue Gao; Mei Wang; Hee-Bum Kang; Yaozhu Pan; Shuangping Liu; Young Rock Chung; Omar Abdel-Wahab; Taha Merghoub; Michael Rossi; Ragini R Kudchadkar; David H Lawson; Fadlo R Khuri; Sagar Lonial; Jing Chen
Journal:  Mol Cell       Date:  2018-03-15       Impact factor: 17.970

Review 6.  Chondroitin sulphate: a focus on osteoarthritis.

Authors:  Mamta Bishnoi; Ankit Jain; Pooja Hurkat; Sanjay K Jain
Journal:  Glycoconj J       Date:  2016-05-19       Impact factor: 2.916

Review 7.  Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis.

Authors:  Olivier Bruyere; Jean-Yves Reginster
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

8.  Longitudinal use of complementary and alternative medicine among older adults with radiographic knee osteoarthritis.

Authors:  Shibing Yang; Catherine E Dubé; Charles B Eaton; Timothy E McAlindon; Kate L Lapane
Journal:  Clin Ther       Date:  2013-10-18       Impact factor: 3.393

9.  Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids.

Authors:  Jörg Jerosch
Journal:  Int J Rheumatol       Date:  2011-08-02

10.  An observational cohort study to assess N-acetylglucosamine for COVID-19 treatment in the inpatient setting.

Authors:  Ameer E Hassan
Journal:  Ann Med Surg (Lond)       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.